Form 4: Halozyme Therapeutics Director Sells Shares Under 10b5-1 Trading Plan

Jeffrey William Henderson, a director at Halozyme Therapeutics, sold shares of common stock on February 3, 2025, under a pre-arranged trading plan.

Summary

• On February 3, 2025, Jeffrey William Henderson, a director of Halozyme Therapeutics, Inc., sold shares of the company's common stock.
• The sales were executed under a pre-arranged trading plan adopted on September 17, 2024, in accordance with Rule 10b5-1.
• A total of 1,100 shares were sold at a weighted average price of $55.943, with individual prices ranging from $55.22 to $56.21.
• An additional 3,900 shares were sold at a weighted average price of $56.405, with individual prices ranging from $56.22 to $56.98.
• Following these transactions, Henderson directly owns 38,611 shares of Halozyme Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting a director's stock sales under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company directors are a normal part of corporate governance. The use of a 10b5-1 trading plan allows insiders to sell shares without being accused of acting on inside information.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates concerns about insider trading.

Key Dates

Keywords

Form 4, Halozyme Therapeutics, Director, Share Sale, 10b5-1 Trading Plan, Insider Trading